Tech Company Financing Transactions

Kate Therapeutics Funding Round

Kate Therapeutics, based in San Diego, secured $51 million in funding from Versant Ventures, Westlake Village BioPartners and Osage University Partners.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
The company intends to use the funds to support the advancement of its initial internal portfolio of muscle and heart disease programs, including myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), which are two of the leading causes of adult-onset muscular dystrophy.

Company Information

Company Status
Private & Independent
Mailing Address
10675 Sorrento Valley Rd 150
San Diego, CA 92121
Email Address
Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases. We are based in San Diego, California. Kate Therapeutics is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapy and enable the pursuit of a broader set of disease targets that are otherwise difficult to drug with current technologies. Data supporting one of our approaches to improve AAV-mediated gene delivery has been published (Tabebordbar et al., Cell, 2021). Our novel capsids provide superior muscle and heart transduction and liver de-targeting compared to the naturally occurring serotypes currently used in clinical trials. This may enable more complete tissue transduction at significantly lower and safer doses, addressing a major limita
Kate Therapeutics LinkedIn Company Profile
Social Media
Kate Therapeutics Company Twitter Account
Company News
Kate Therapeutics News
Kate Therapeutics on Facebook
Kate Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Kevin Forrest
  Kevin Forrest LinkedIn Profile  Kevin Forrest Twitter Account  Kevin Forrest News  Kevin Forrest on Facebook
Chief Medical Officer
Christopher Kurt
  Christopher Kurt LinkedIn Profile  Christopher Kurt Twitter Account  Christopher Kurt News  Christopher Kurt on Facebook
Chief Scientific Officer
Sharif Tabebordbar
  Sharif Tabebordbar LinkedIn Profile  Sharif Tabebordbar Twitter Account  Sharif Tabebordbar News  Sharif Tabebordbar on Facebook



Browse more venture capital transactions:

Prev: 6/8/2023: HyperPlay venture capital transaction
Next: 6/8/2023: eFFECTOR Therapeutics venture capital transaction


Share this article


About Database of VC Transactions

We report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary